Catalent to Spend $100 Million on Italian Drugs Plant
Catalent to Spend $100 Million on Italian Drugs Plant
GALWAY, IRELAND--August 16, 2021--Written by Martin Lynch, European News
Editor for Industrial Info (Galway, Ireland)--Catalent (NYSE: CTLT) (Somerset, New Jersey), a leading contract development and manufacturing organization (CDMO), has kicked off a $100 planned expansion of its Italian facility in Anagni.
Within this article: Details project investment, timelines, existing COVID-19 vaccine fill & finish contracts
Subscribe Now!(All Fields Required)
Related Articles
Articles related to this company
- Novo Nordisk Spends $11 Billion to Make More Weight Loss Drugs
- AstraZeneca Plans to Supply Europe with 400 Million Doses of COVID-19 Vacci...
- Big Pharma Reacts to Russia's Move on Ukraine
- EU Adds New COVID-19 Manufacturing Capacity
- Pfizer-BioNTech, Moderna and Johnson & Johnson Ramp Up COVID-19 Vaccines fo...